U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905054) titled 'Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation' on Feb. 28.
Brief Summary: This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Primary Sclerosing Cholangitis
Liver Transplant, Complications
PSC
Biliary Strictures
Intervention:
DRUG: Fenofibrate (drug)
Once daily fenofibrate for 36 months
DIAGNOSTIC_T...